VANCOUVER, British Columbia, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics announced that management will be hosting a web-based seminar (Webinar) to provide a corporate update on its pipeline of therapeutic candidates on Tuesday, October 8, 2013 at 4:00 pm ET / 1:00 pm PT.
A live feed of the presentation slides and audio will be available on the "Investors" section of the company's website at www.tekmirapharm.com. To participate in the Webinar, please register at http://investor.tekmirapharm.com/events.cfm. Questions can be submitted online during the Webinar using the Q&A tab of the webcast player. A replay of the Webinar will be available on the Tekmira website approximately 24 hours after the event.
Questions may also be submitted in advance by pre-registering for the Webinar at http://investor.tekmirapharm.com/events.cfm and accessing the Q&A tab at the bottom of the webcast player, or sending an email directly to jregts@tekmirapharm.com with "Webinar Q&A" in the subject line.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.